Skip to main content

Table 1 Distributions of baseline variables by treatment arm, according to prognostic Okuda subgroups

From: Tamoxifen is not effective in good prognosis patients with hepatocellular carcinoma

Okuda category

I-II

III or unknown

 

Tamoxifen (n = 189)

Control (n = 196)

Tamoxifen (n = 48)

Control (n = 44)

Median (range) age, years

66 (39–91)

67 (42–84)

62 (37–86)

66 (31–80)

Men

133 (70.4)

144 (73.5)

36 (75.0)

39 (88.6)

Evidence of disease at entry

178 (94.2)

184 (93.9)

40 (83.3)

39 (88.6)

Interval between diagnosis and entry

    

   0–6 months

150 (79.4)

161 (82.1)

44 (91.7)

38 (86.7)

   7–12 months

20 (10.6)

15 (7.7)

1 (2.1)

4 (9.1)

   13–24 months

19 (10.1)

20 (10.2)

6 (6.3)

2 (4.6)

Child-Pugh category

    

   A

90 (47.6)

98 (50.0)

25 (52.1)

20 (45.6)

   B

82 (43.4)

75 (38.3)

13 (27.1)

11 (25.0)

   C

17 (9.0)

23 (11.7)

9 (18.8)

12 (27.3)

   unknown

0 (0.0)

0 (0.0)

1 (2.1)

1 (2.3)

Locoregional treatment

    

   Surgery

11 (5.8)

12 (6.1)

7 (14.6)

3 (6.8)

   Percutaneous Ethanol Injection

61 (32.3)

72 (36.7)

3 (6.3)

6 (13.6)

   Transarterial chemoembolization

31 (16.4)

33 (16.8)

11 (22.9)

5 (11.4)

   none

86 (45.5)

79 (40.3)

27 (56.3)

30 (68.2)